Onge ยท Nauru
US Adds Three Chinese Entities to Xinjiang-Linked List: What Foreign Founders Need to Know
China's commerce ministry pushed back on new US entity-list additions tied to the so-called Xinjiang forced labor act, warning of countermeasures. Here is what the dispute means for foreign founders building or running companies in China.
A New US Listing and a Sharp Chinese Response
On October 28, US East Coast time, the US Department of Homeland Security announced that three additional Chinese entities would be added to the entity list created under the so-called Uyghur Forced Labor Prevention Act. China's Ministry of Commerce spokesperson was asked for comment and issued a formal response, published by the ministry's news office on October 29.
For foreign founders registering or operating a company in China, the exchange matters less as a political story than as a signal about compliance risk, supply-chain exposure, and the operating environment for cross-border businesses. The following summarizes what the ministry said, using only the facts in the official statement.
What the Spokesperson Said
Denial of the Underlying Allegation
The spokesperson said China does not have forced labor, that workers of all ethnic groups in Xinjiang enjoy free and equal employment, and that their labor rights are effectively protected in accordance with the law. On that basis, the ministry characterized the US measures as lacking any factual foundation.
Characterization of US Motives
According to the statement, the United States continues to manipulate human rights issues and uses the human rights label as a cover for unilateral protectionism and bullying. The spokesperson expressed strong condemnation and firm opposition on behalf of China.
Reference to Earlier Listings and Countermeasures
The spokesperson noted that the United States had already added a large number of Chinese entities to the so-called Xinjiang act entity list not long before this latest action. China said it had made solemn representations to the US side and had taken firm countermeasures in response.
The New Element: Biomedical Technology Firms
The statement says the US side did not change course and, despite China's firm opposition, proceeded with new sanctions measures, adding Chinese biomedical technology enterprises to the sanctions list. Foreign founders in life sciences or healthcare supply chains should note this specific sector reference in the official text.
Stated Consequences for Bilateral Commercial Relations
The ministry said the listing approach runs counter to the consensus reached by the heads of state of the two countries, seriously undermines the stability of China-US economic and trade relations, and is also contrary to the spirit of humanitarianism. It called on the US side to immediately stop political manipulation and smear campaigns and to stop the unreasonable suppression of Chinese enterprises. China said it would take necessary measures to firmly safeguard its own interests.
Why This Matters for Foreign Founders in China
The statement is a government reaction to a specific US action, not a change in Chinese company law or foreign investment rules. Still, founders should read it as a reminder of several practical realities.
- Entity listings can affect supply chains. When Chinese entities are added to US lists, counterparties in the United States may face restrictions or heightened due diligence. A foreign-invested company in China sourcing from or selling to affected entities could see contract reviews, payment delays, or requests for additional documentation.
- Sector attention is broadening. The statement specifically mentions biomedical technology enterprises, suggesting that founders in health-related fields should keep their compliance mapping current.
- Bilateral friction is explicitly acknowledged. The ministry says the listings undermine the stability of China-US economic and trade relations, which is a direct signal that cross-border operators should expect continued volatility in the policy environment.
- Countermeasures are stated, not detailed. China says it will take necessary measures to protect its interests. The statement does not specify what those measures are, so founders should avoid assuming any particular outcome.
- Documentation discipline pays off. Because the dispute centers on factual claims about labor practices, companies with transparent supply-chain records and clear employment documentation are better positioned to answer questions from banks, customers, and investors.
Practical Steps to Consider
Map Your Exposure
Review your Chinese subsidiary's customers, suppliers, and logistics partners against publicly available US list information. Identify any contracts that contain list-related termination or compliance clauses.
Keep Employment Records Orderly
Ensure labor contracts, payroll, working hours, and social insurance records for your China entity are complete and consistent. This is ordinary good practice, but it becomes more valuable when cross-border buyers ask questions about labor conditions.
Watch for Sector-Specific Developments
Founders in biotech, pharmaceuticals, and medical devices should monitor official Chinese and US announcements, since the latest action named biomedical technology enterprises specifically.
Build Local Advisory Support
Because the statement leaves countermeasures undefined, maintain relationships with local counsel and business associations that can provide timely interpretation of new measures.
Separate Political Noise from Legal Obligations
Nothing in the statement changes China's foreign investment framework. Registration, capital, tax, and licensing obligations for foreign-invested enterprises continue under existing rules. Treat the announcement as risk context, not as a change in formation requirements.
What the Statement Does Not Say
The official response does not name the three entities, does not describe the products involved, and does not set out specific retaliatory measures. It also does not address how foreign-invested companies should respond. Founders should therefore avoid reading into the text anything beyond what is stated.
Bottom Line
The Ministry of Commerce has condemned the new US listings, rejected the factual basis for them, referenced earlier countermeasures, and warned that bilateral commercial stability is at stake. For foreign founders operating in China, the practical takeaway is to strengthen compliance documentation, monitor sector-specific risk, and stay informed about both US listing actions and any Chinese response measures as they are announced.
Foreign founders who need support with company registration, compliance documentation, or ongoing operations in China can contact ChinaMNC on WhatsApp or WeChat at +86 153 1898 8535.
This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.